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Summary
PRINCIPLES: To assess the efficiency and complication
rates of vaso-occlusion of pulmonary arteriovenous mal-
formations (PAVMs) in Rendu-Osler-Weber disease
(hereditary haemorrhagic telangectasia; HHT).
METHODS: Seventy-two patients were investigated in our
institution for HHT between March 2000 and November
2011. Sixteen presented PAVMs (22.2%), and 11 (68.8%)
were treated with vaso-occlusion for a total of 18 proced-
ures. Procedures included coils, plugs and combined ap-
proaches. Immediate success and recurrence rate, complic-
ation were recorded, as well as persistent and new PAVMs
during clinical and computed tomography (CT) follow-up.
RESULTS: Eighteen procedures were performed and a
total of 37 PAVMs were treated, 19 with coils, 16 with
plugs and 2 with combined treatment. Mean CT follow-up
time was 41 months (1‒164). No major complication was
observed. One distal translocation was treated during the
same intervention. Two PAVMs persisted after treatment
(5.7%), both treated by means of plug embolisation. One
new PAVM was observed during follow-up CT. PAVMs
with an afferent artery of less than 3mm or asymptomatic
PAVMs were not treated.
CONCLUSION: Recent studies have demonstrated that
vaso-occlusion has become the gold standard treatment for
PAVM. This study is in accordance with previous results
and shows a minimal complication rate and little recur-
rence, whether by coils, plugs, or combined treatments.
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Introduction
Pulmonary arteriovenous malformations (PAVM) are a rare
disorder in the general population, with an estimated pre-
valence at autopsy of 3:15'000, although no population-
based studies are available to determine its real incidence
[1]. The vast majority of PAVMs (80%‒95%) are dia-
gnosed in patients presenting with hereditary haemorrhagic
telangiectasia (HHT) or Rendu-Osler-Weber disease (fig.
1) [2]. HHT is a rare genetic autosomal-dominant disease
caused by mutations in five to six genes, the most studied
and known being ENG (on chromosome 9), ALK1 (on
chromosome 9) and SMAD4 ((on chromosome 18). All
Figure 1
Maximun intensity imaging and 3D reconstructions of pulmonary
computed tomography angiography showing numerous pulmonary
arteriovenous malformations in a female 50 years old female
patient known to have hereditary haemorrhagic telangectasia.
Figure 2
Treatment for symptomatic or >3 mm pulmonary arteriovenous
malformations and follow-up.
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 10
three genes are involved in the cascade resulting in the
transforming growth factor-beta (TGF-β) [3]. Genetic test-
ing has been made available for these three known genes,
allowing identification of approximately 80% of affected
patients. Penetrance is age-related and is almost complete
by the age of 40 years old [4]. Current clinical diagnostic
criteria, called Curaçao criteria, include epistaxis, muco-
cutaneous telangiectasia, visceral AVMs (pulmonary, hep-
atic, cerebral, spinal AVMs, gastrointestinal telangiectasia)
and family history [5, 6]. HHT is a rare disease. A large
epidemiological study in France by Bideau and Plauchu
showed a prevalence of 1/8,345 in France [7]. At the time
of writing, no such study is available in Switzerland, but
two out of three French regions with higher prevalences (1/
3,375 in the Ain department and 1/5,062 in Jura) are loc-
ated near Swiss borders, with patients from these regions
being followed in our institution, for geographical proxim-
ity reasons.
Figure 3
Examples of pulmonary arteriovenous malformation endovascular
vaso-occlusions with vascular coils, plugs and combined treatment.
Beneath each case is an angiographic control showing no vascular
opacification beyond the occlusive device.
Figure 4
Embolisation attempt of a large pulmonary arteriovenous
malformation (PAVM) with a feeding artery of 12 mm diameter with
a 10/5 mm 10.035 Tornado® coil. Owing to the size of the AVM,
distal translocation of the coil in the left ventricle occurred. A snare-
assisted removal was then performed before a second and
successful attempt at occluding this PAVM.
The prevalence of PAVM in patients with HHT is estimated
to be between 30% and 50% [8]. A PAVM results in an
arteriovenous shunt bypassing the capillary bed and de-
priving the blood flow of oxygenation and a filtering mech-
anism. Thus complications of PAVMs include hypoxaemia
from the right to left shunt, stroke, transient ischaemic at-
tack, brain abscess, migraines, decompression illness, hae-
moptysis and haemothorax [8–11]. Percutaneous transcath-
eter vaso-occlusion (PTV) has been demonstrated to be the
gold standard treatment of PAVM. It has been shown to be
effective in improving arterial oxygenation and in reducing
right-to-left anatomic shunt fraction [12]. Advantages over
surgical interventions include being less invasive and easy
to repeat. Surgery is no longer considered in first intention.
Disadvantages include collateralisation and revascularisa-
tion over time [3]. It has been advocated that, regardless
of symptoms, any PAVM with a feeding artery of ≥3 mm
in diameter should be considered for PTV [3, 13]. Embolic
devices consist of vascular coils and/or vascular plugs [14].
In this context, the purpose of this study was to report our
experience and assess the efficiency and complications of
endovascular treatment of PAVMs in HHT in our institu-
tion.
Materials and methods
Clinical and radiological data of 72 consecutive patients
(38 females, 34 males, mean age 58 years) investigated in
our institution for HHT between March 2000 and Novem-
ber 2011 were reviewed. Anamnestic data, genetic invest-
igations and clinical follow-up were gathered by the pneu-
monology department of our institution. Thoracic com-
puted tomography angiography (CTA) was prescribed on
the basis of clinical suspicion [3]. When a PAVM was dia-
gnosed, assessment of the number and size of PAVMs, and
feasibility of treatment were assessed. Criteria for treat-
ment were: afferent artery diameter >3 mm, history of
paradoxical embolism with recognisable responsible ves-
sel, and hypoxaemia with a left-to-right shunt. Based on
CT findings, endovascular treatment was proposed to the
patient. Standard vaso-occlusion procedures are performed
with local anaesthesia. A standard 6F or 8F 65 cm long in-
troducer sheath (6F or 8F 6 Fr. x 25-5/8" (65 cm) Super
Arrow-Flex®, Teleflex, Arrow intl, PA, USA) was posi-
tioned in the main pulmonary artery, then a selective 5F
catheter was used to reach the pulmonary artery branch and
a microcatheter was used in order to be superselective (fig.
Figure 5
Examples of Hyperion™ vascular plugs (a, b) and a Tornado®
Embolization Coil (c)
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4). Available endovascular treatment devices consisted of
vascular coils and vascular plugs. No balloon was used.
Vascular platinum coils (Tornado® Embolization Coil,
Cook Medical, Bloomington, IN, USA) are the core of
PAVM vaso-occlusion [3, 15]. They consist of linear plat-
inum coils with polyester fibres over the surface that, once
out of the catheter, take a spherical or a spiral shape and oc-
clude the vessel. Amplatzer Vascular Plugs (Amplatzer™,
St Jude Medical, Little Canada, Minnesota, USA) are self-
expandable, cylindrical devices made from a Nitinol wire
mesh secured on both ends with platinum marker bands. A
stainless steel micro screw is welded to one of the platin-
um marker bands. The devices were pushed by a 135 cm
pusher wire. In our study, type I and type IV Amplatzer
plugs were used, with a diameter range between 4 and 8
mm. Hyperion vascular plugs (Hyperion™, Comed B.V.,
Bolsward, The Netherlands) are self-expandable wire mesh
devices with different shapes (fig. 5), pushed by a 110 cm
long loader. After the confirmation of the right position,
the plug is deployed into the feeding artery. When recanal-
isation was feared, because of the size or of the complex-
ity of the PAVM, a combined plug and coil vaso-occlusion
was made, in accordance with previous studies [16] (fig.
4). Angiographic control was made to confirm the occlu-
sion of the feeding artery and the absence of distal trans-
location. Follow-up CT was advised 6–12 months after the
treatment and every 3 years thereafter [6]. CT protocol con-
sisted of helicoidal CT acquisition with Iodine contrast me-
dia injection in pulmonary arterial time. Statistical anaylsis
was made using Microsoft® Excel (Microsoft, Redmond,
USA). All patients benefitted from a clinical follow-up.
Table 1: Patient demographics and number of procedures.
Number of patients with HHT 72
Mean age 58 y
(20–93)
Patients with PAVMs 16 (22.2%)
Treated patients with PAVMs 11 (68.7%)
Male:female ratio 1:1.67
Total PAVMs 54
Total treated PAVMs 37
Mean PAVMs per patient 3.9 (1–12)
Total procedures 18 (1–4)
Total recurrence rate per treated PAVM 5.4%
Mean Follow-up time 41 m
(1–164)
New PAVM per year 0.29/y
HHT = hereditary haemorrhagic telangiectasia; PAVM = pulmonary
arteriovenous malformation
Results
A total of 16 patients out of 72 followed-up for HHT
(22%, 10 women, 6 men, m:f 1:1.67) presented a total of
54 PAVMs (1‒12, mean 3.9 PAVMs per patient,). Mean
follow-up CT time was 41 months (1‒164). Based on the
above-mentioned criteria for treatment, 11 patients were
treated with vaso-occlusion for a total of 37 PAVMs
throughout 18 procedures including 2 second treatments
for 2 PAVMs (table 1). Eight patients were symptomatic
and three presented asymptomatic PAVMs with feeding ar-
teries larger than 3 mm (fig. 2). Mean procedures per pa-
tient was 1.64. Total treated PAVMs per total PAVM was
37/54 (68.5%). Nineteen PAVMs were treated with coils,
16 with plugs and 2 with combined treatment (table 2, fig.
3). Thirty-four (91.9%) PAVMs were successfully treated
on the first intervention. Total recurrence rate per patient
was 18.2% (2/11). Total recurrence rate per procedure was
12.5% (2/16). Total recurrence rate per treated PAVM was
5.4% (2/37). Two PAVMs (5.4%) treated by means of plugs
needed a second procedure (at 10 days and 3 months), both
treated by use of Amplatzer plugs. One case of a volumin-
ous PAVM presented a large afferent artery of 12 mm dia-
meter. A 15 mm long coil was initially used, but migrated
into the main pulmonary artery and required a snare-as-
sisted coil retrieval. Then a smaller sized 10/5 mm Tor-
nado® coil was released, but it migrated distally into the
left atrium, the left ventricle and finally the mitral valve.
A snare-assisted coil retrieval was again successfully at-
tempted (fig. 3). No clinical manifestation was observed. A
second intervention a month later allowed for a coil-assis-
ted successful vaso-occlusion, using multiple coils between
5 and 10 mm. Eighteen (94.7%) plug-treated PAVMs were
successfully treated on the first intervention compared with
14 (87.5%) for coil vaso-occlusion, but Fisher’s test gave a
p = 0.58 value, considered not significant. One new PAVM
was observed during follow-up CT (0.29 per year) and was
not treated because of its size. After the first intervention,
mean procedure number per patient during follow-up was
0.63 (6 interventions for 11 patients). No major complica-
tion was observed. No surgery was needed in our series.
Discussion
HHT is a heterogenous, autosomal dominant disorder char-
acterised by recurrent epistaxis, mucocutaneous tel-
angiectasia, visceral, pulmonary and cerebral arteriovenous
malformations. Its incidence in the general population is
estimated to be 1:5,000 to 1:8,000 with a penetrance ap-
proaching 97% by age 45 years. PAVMs are a rare condi-
tion in the general population with an approximated incid-
ence estimated at 3:100,000. Treatment is adapted to the
Table 2: Results of embolotherapy by method. Recurrent pulmonary ateriovenous malformations (PAVMs) occurred in patients treated with vascular plugs at 10 days and 3
months.
Embolotherapy method Number of treated
PAVMs
Number of
procedures
Number of devices
used
Size range Distal translocation Recurrent PAVM
Coil 19 9 20 3/7 – 5/10 1 0
Plug 16 7 18 4–8 mm 0 2
Combined treatment 2 2 2 0 0
Total 37 18
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number, to the size and to the diffusion of PAVMs [17].
Since about 90% of PAVMs occur in patients with HHT,
diagnosis and clinical follow-up of affected patients is crit-
ical for detecting and treating this condition. Therefore, a
close interaction between the referring clinician, a refer-
ral centre and the interventional radiologist is beneficial
for optimising diagnosis, treatment and follow-up. Vaso-
occlusion is now recognised as the standard of care for
patients with HHT and a PAVM with a feeding artery of
>3 mm [18]. Immediate vaso-occlusion has been proven
to correlate with improved life expectancy and quality-ad-
justed survival rates [3]. The incidence of PAVMs in our
group followed for HHT (22%) was a little lower than pre-
vious estimates. Female-to-male ratio was consistent with
previous studies. In our group, 50% of patients presen-
ted with multiple PAVMs at the time of initial diagnosis
(35%–65% in the literature). Imaging diagnosis was made
with pulmonary CTA, considered to be the gold standard
diagnostic tool as it allows easy screening, high resolution
and definition of the type of PAVMs [4, 17]. Angiographic
magnetic resonance was ruled out as it was less efficient
than CTA. Endovascular treatment is made by means of
transcatheter vaso-occlusion. PAVMs, even asymptomatic,
with a feeding vessel 3 mm in diameter or more should
be treated. Historically, vaso-occlusion treatments mainly
consisted of detachable occlusion balloons. They were re-
moved from US markets in 2002 [19], and were prone to
deflate [20]. Onyx and glue vaso-occlusions are not indic-
ated as a result of the relatively large diameter size of affer-
ent arteries of treatable PAVMs [21]. The device of choice
then consisted of vascular coils. Advantages include a wide
array of sizes and the great flexibility of the device. Dis-
advantages include distal migration, which is attenuated by
the use of detachable coils. Vascular plugs, such as Am-
platzer or Hyperion plugs may also be used, especially for
PAVMs with larger feeding vessels [22]. First generation
plugs did not present a favourable morphology and were
not adapted to pulmonary artery anatomy, but current gen-
eration and recent studies show favourable outcomes [23].
A combined coil and plug approach has been described in
the case of complex or large afferent artery cases [16]. In
our series, the choice between coils and plugs depended
on multiple factors, such as the size of the afferent artery,
but also the specific anatomy of the PAVM and its feed-
ing vessel, so that the choice of which device to use is
still depending on each specific situation. Only one case
presented with distal coil translocation in the context of a
large feeding artery (12 mm); this diameter proved diffi-
cult to treat with either coil or plug vaso-occlusion. Larger
studies are needed to assess the efficiency of both devices
in these specific situations. Recurring PAVMs needing a
second treatment only occurred with vascular plugs, but be-
cause of the small number of recanalisations (n = 2, 5.4%
of treated PAVMs), an association with the vaso-occlusion
device could not be determined. New vascular plugs such
as Hyperion plugs look promising, but further studies are
needed to assess their efficiency.
PAVMs are frequent in HHT and their potential complic-
ations call for a rigorous detection, diagnosis and treat-
ment, which can be achieved by specialised clinical as-
sessment and follow-up and close collaboration with the
interventional radiologist. Our series correlates with pre-
vious studies showing the overall excellent success rates
of endovascular treatment of PAVMs which are compliant
with current treatment criteria. Whereas plugs and coils
give excellent final results, statistical comparison didnot
show a significant difference in outcome; moreover, the
variety of factors determining which device to use did not
allow for a feasible comparison study. Further studies are
needed to assess the efficiency of each device with defined
criteria.
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Figures (large format)
Figure 1
Maximun intensity imaging and 3D reconstructions of pulmonary computed tomography angiography showing numerous pulmonary
arteriovenous malformations in a female 50 years old female patient known to have hereditary haemorrhagic telangectasia.
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Figure 2
Treatment for symptomatic or >3 mm pulmonary arteriovenous malformations and follow-up.
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Figure 3
Examples of pulmonary arteriovenous malformation endovascular vaso-occlusions with vascular coils, plugs and combined treatment. Beneath
each case is an angiographic control showing no vascular opacification beyond the occlusive device.
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Figure 4
Embolisation attempt of a large pulmonary arteriovenous malformation (PAVM) with a feeding artery of 12 mm diameter with a 10/5 mm 10.035
Tornado® coil. Owing to the size of the AVM, distal translocation of the coil in the left ventricle occurred. A snare-assisted removal was then
performed before a second and successful attempt at occluding this PAVM.
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Figure 5
Examples of Hyperion™ vascular plugs (a, b) and a Tornado® Embolization Coil (c)
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